RNase H2 Loss in Murine Astrocytes Results in Cellular Defects Reminiscent of Nucleic Acid-Mediated Autoinflammation

Karen Bartsch1†, Markus Damme1†, Tommy Regen2, Lore Becker3, Lillian Garrett3,4, Sabine M Höltter3,4, Katharina Knittler1, Christopher Borowski1, Ari Waismann2, Markus Glatzel5, Helmut Fuchs1, Valerie Gailus-Durner3, Martin Hrabe de Angelis3,6,7 and Björn Rabe1*

1Medical Faculty, Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany, 2Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 3German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, 4Institute of Developmental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, 5Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 6Chair of Experimental Genetics, School of Life Science Weihenstephan, Technische Universität München, Freising, Germany, 7German Center for Diabetes Research (DZD), Neuherberg, Germany

Aicardi–Goutières syndrome (AGS) is a rare early onset childhood encephalopathy caused by persistent neuroinflammation of autoimmune origin. AGS is a genetic disorder and >50% of affected individuals bear hypomorphic mutations in ribonuclease H2 (RNase H2). All available RNase H2 mouse models so far fail to mimic the prominent CNS involvement seen in AGS. To establish a mouse model recapitulating the human disease, we deleted RNase H2 specifically in the brain, the most severely affected organ in AGS. Although RNase H2ΔGFAP mice lacked the nuclease in astrocytes and a majority of neurons, no disease signs were apparent in these animals. We additionally confirmed these results in a second, neuron-specific RNase H2 knockout mouse line. However, when astrocytes were isolated from brains of RNase H2ΔGFAP mice and cultured under mitogenic conditions, they showed signs of DNA damage and premature senescence. Enhanced expression of interferon-stimulated genes (ISGs) represents the most reliable AGS biomarker. Importantly, primary RNase H2ΔGFAP astrocytes displayed significantly increased ISG transcript levels, which we failed to detect in in vivo brains of RNase H2ΔGFAP mice. Isolated astrocytes primed by DNA damage, including RNase H2-deficiency, exhibited a heightened innate immune response when exposed to bacterial or viral antigens. Taken together, we established a valid cellular AGS model that utilizes the very cell type responsible for disease pathology, the astrocyte, and phenocopies major molecular defects observed in AGS patient cells.

Keywords: Aicardi–Goutières syndrome, RNase H2, interferon signature, DNA damage, cellular senescence

INTRODUCTION

Aicardi–Goutières syndrome (AGS) is an inherited autoimmune disorder typically affecting the brain and, to a lesser extent, also the skin. Its neurological symptoms include leukodystrophy, microcephaly, and calcifications within the basal ganglia and white matter (1). Disease onset is typically during the first year of life, although in about 20% disease symptoms manifest already at birth or in utero.
In the affected neonates, clinical signs of AGS mimic the sequelae of congenital virus infections. AGS is caused by mutations in the genes *TREX1*, *RNASEH2*, *SAMHD1*, *ADAR1*, or *IFIH1*, with RNase H2 mutations accounting for >50% of all cases (2). RNase H2 is a trimeric enzyme consisting of the subunits A (catalytic), B, and C, whereby all three subunits can be mutated, although individually, in AGS patients. With the exception of IFIH1, which encodes the cytosolic RNA sensor MDA5, all proteins associated with AGS are involved in nucleic acid metabolism. It has therefore been proposed that in AGS endogenous nucleic acids accumulate, thereby stimulating the innate immune system to produce increased amounts of the antiviral cytokine interferon α (3). While elevated interferon α levels are found in AGS patients in the cerebrospinal fluid and to a lesser extent also in serum, mRNA expression of interferon-stimulated genes (ISGs) in peripheral blood has turned out to be the most reliable AGS biomarker to date (4). This so-called interferon signature is also a hallmark of systemic lupus erythematosus (SLE), which shares many clinical features with AGS (3, 5). Post-mortem analysis of diseased brains has established astrocytes as the cellular source of interferon α in AGS (6). In line with this, transgenic mice that constitutively express interferon α in astrocytes develop neurological symptoms similar to AGS, suggesting that AGS is driven by chronic cerebral presence of interferon α (7). A striking feature of all previous AGS mouse models is that none seems to recapitulate the strong CNS involvement associated with the human disease. *TREX1* knockout (KO) mice for instance exhibit multi-organ autoimmunity and eventually succumb to sterile myocarditis, which is accompanied by strong stimulation of the type I interferon axis mainly in the heart but also in other tissues. The brain, however, is not affected in *TREX1* KO mice (8, 9). Both *ADAR1* and RNase H2 KO mice die during embryogenesis, with only *ADAR1* KO embryos displaying marked type I interferon upregulation (10–12). *SAMHD1*-deficient mice on the other hand have no obvious phenotype, but exhibit a weak interferon signature in selected organs (13, 14). Mice bearing a gain-of-function *IFIH1* mutation show lupus-like systemic autoimmunity, again without CNS involvement (15). Two hypomorphic RNase H2 mouse models have been generated recently and depending on the introduced patient mutation, the animals die perinatally (G37S mutation in the catalytic A subunit) or display no overt phenotype (A177T mutation in the accessory B subunit) (16, 17). Although both mouse models exhibit ISG upregulation in some tissues, no signs of neuroinflammation were apparent. The differences in disease presentation in terms of CNS involvement between AGS patients and the corresponding mouse models are striking, yet the underlying reasons are unclear. Given the absence of a CNS-related phenotype in hypomorphic RNase H2 mice and the early embryonic lethality of RNase H2 null mice, we generated conditional knockout mice devoid of RNase H2 in large parts of the brain (RNase H2ΔGFAP mice) in an attempt to establish an RNase H2-based mouse model of AGS. In contrast to the severe phenotype associated with human disease, but in line with other AGS models, mice lacking RNase H2 in astrocytes and neurons displayed no clinical signs of disease. However, astrocytes isolated from RNase H2ΔGFAP mice exhibited cellular defects reminiscent of AGS. We believe that the RNase H2-deficient astrocytes generated in this study can serve as a valid cellular model for AGS, especially as they represent the very cell type considered to govern the pathogenic interferon α expression in human patients.

**MATERIALS AND METHODS**

**Mice**

RNase H2flox mice, the generation of which was described in Ref. (11), were kindly provided by Axel Roers (Institute of Immunology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Dresden, Germany). Floxed RNase H2B mice were crossed to Cre-hGFAP mice (18) for gene inactivation in astrocytes as well as cortical and hippocampal neurons and resulting RNase H2BΔlox/lox, hGFAP-Cre mice were termed RNase H2ΔGFAP mice. For RNase H2 ablation in neurons of the neocortex and hippocampus floxed RNase H2B mice were intercrossed with Cre-Emx1 mice (19) and RNase H2BΔlox/lox, Emx1-Cre mice were termed RNase H2ΔEmx1 mice. RNase H2BΔlox/lox littersmates w/o Cre served as control animals. All mice were provided with food and water *ad libitum* and maintained in a 12-h light–dark cycle under standard conditions at Kiel University. Genotyping PCR was performed on processed tail clips (Direct PCR Lysis Reagent Tail, Peqlab), whereby respective PCR protocols as well as primer sequences were obtained from www.jax.org. Procedures involving animal care were conducted in accordance with national and international laws and policies with appropriate permission. All experiments were carried out in accordance with the guidelines for Animal Care of the Christian-Albrechts-University of Kiel.

**Generation and Treatment of Primary Astrocytes**

For astrocyte isolation, P3/4 pups were decapitated, their brains taken out, and meninges carefully removed under a dissecting microscope. Cerebral hemispheres were minced with a scalpel and digested in HBSS complemented with 2.5% trypsin (v/v) and 1% DNase I (m/v) for 30 min at 37°C (water bath). During digestion, the suspension was disintegrated every 10 min using a 1 ml pipet. Afterwards the cell suspension was filtered through a 40 µm cell strainer and the filtrate topped up with two volumes minimum essential medium (MEM). Following centrifugation for 3 min at 1,300 g, cells were resuspended in glia medium 1 (MEM complemented with 10% horse serum, 0.6% glucose, and 1% penicillin/streptomycin) and dispensed into three 6-wells coated with 0.1 mg/ml poly-L-lysine. After 48 h, culture medium was changed to glia medium 2 (Dulbecco's modified Eagle's Medium, high glucose 4.5 g/l, with GlutaMAX™, supplemented with 10% FCS, N2 Supplement, 1 µg/50 ml epidermal growth factor, and 1% penicillin/streptomycin) in which cells were cultured at 37°C, 5% CO2, and 3% O2 until experimental use. Upon confluency, control and RNase H2ΔGFAP astrocytes were splitted 1:6 and 1:2, respectively, using Accutase and Trypsin/EDTA (2:3, Sigma Aldrich). A day prior to experiments microglia were removed from cell suspensions by multiple thorough PBS washing steps. The primary astrocyte culture consistently contained >90% GFAP-positive cells. Astrocytes were treated with Doxorubicin (1 µM for 18 h) and LPS (*E. coli* 0111:B4, 500 ng/ml, 6 h, both Sigma Aldrich) or transfected with
polyIC (5 µg, 6 h, Invivogen). To drive astrocytes into oncogene-induced senescence (OIS), cells were retrovirally transduced with H-RasG12V 4 days post isolation, as described in Ref. (20). Successful transfectants were enriched by 500 µg/ml puromycin (Sigma Aldrich) treatment for another 6 days and senescent astrocytes were harvested and analyzed 10 days post isolation.

**Immunofluorescence and Immunohistochemistry**

For immunofluorescence analysis, primary astrocytes were fixed with ice-cold acetone/methanol (1:2) for 10 min and blocked with 1% (w/v) BSA in PBS overnight at 4°C. Cells were incubated with primary antibodies for 4 h and secondary antibodies for 2 h in a humidified chamber and subsequently embedded in ImmunoMount (Thermo Fisher Scientific) complemented with 5 µg/ml 4′,6-diamino-2-phenylindole (DAPI, Sigma Aldrich). Anti-histone γH2AX (Cell Signaling, #2577) and rabbit anti-mouse RNase H2 antiserum [kindly provided by Andrew P. Jackson, MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, UK, described in Ref. (12)] were used as primary antibodies, while anti-rabbit Cy3 (GE Healthcare) served as secondary Ab. For immunohistochemistry, mice were perfused transcardially via the left ventricle with PBS followed by 4% PFA (in PBS). Brains were removed and post-fixed additional 4 h by immersion at room temperature. Subsequently, brains were transferred to 30% sucrose (in PBS) overnight. 35 µm thick free floating sections were prepared on a Leica 9,000 s microtome (Leica, Wetzlar, Germany). Sections for immunohistochemistry were blocked with 1.6% H2O2 solution and washed in PBS. Sections for immunohistochemistry and immunofluorescence were rinsed in PBS and subsequently blocked with 4% normal goat serum in PBS containing 0.25% Triton X-100 at room temperature. The sections were incubated overnight at 4°C with gentle agitation. After washing 3× with washing buffer (PBS containing 0.25% TX-100), sections were incubated for 2 h at RT with appropriate secondary antibodies [fluorophore conjugated; AlexaFluor 488 and 594 (Molecular Probes) or biotinylated second antibodies (Vector Laboratories)] diluted in washing buffer. Antibody dilutions are provided in Supplementary Table B. After additional three washes with washing buffer, sections were coverslipped with MOWIOL/DABCO (fluorescence-labeled sections) containing DAPI or incubated with Streptavidin-HRP (ABC Elite Kit, Vector Laboratories) for another 1 h at room temperature followed by another three washes, development with 3,3′-Diaminobenzidin substrate solution, and coverslipped in MOWIOL. A FV1000D Laser Scanning Confocal Microscope (Olympus) equipped with FV10-ASW 4.2 Viewer software was used for image acquisition.

**qPCR, Western Blotting, and FACS**

Total RNA was isolated using the Gene Jet RNA Purification Kit (Thermo Fisher Scientific), while cDNA was generated with Revert Aid Reverse Transcriptase (Thermo Fisher Scientific) according to the manufacturer’s instructions, except a mixture of oligo(dT)18 and random hexamer primers (1:2, Thermo Fisher Scientific) was used. The qPCR reaction contained SYBR Green qPCR Master Mix (Thermo Fisher Scientific), 0.5 µM target specific primer pairs (Table A in Supplementary Material), and 10 ng cDNA template. SYBR Green incorporation was analyzed on a Lightcycler 480 II (Roche Applied Science) according to the following program: initial denaturation at 95°C for 10 min, 45 cycles of denaturation (10 s at 95°C), annealing (20 s at 60°C), and elongation (20 s at 72°C). Relative mRNA expression was calculated based on the ΔΔCp method with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serving as house keeping control. For flow cytometry, detached astrocytes were fixed in 4% PFA (in PBS) for 20 min, saponin-permeabilized for 15 min (using saponin-based permeabilization and wash reagent, Invitrogen), and blocked in 1% BSA (in PBS) for 15 min. Afterward, cells were incubated with FITC-coupled anti-histone γH2AX (Cell Signaling, #9719) for 1 h on ice and resulting fluorescence was detected using a FACSCanto flow cytometry system (BD biosciences). Western Blot analysis was performed as described in Ref. (21) and the following primary antibodies were used: anti-LAMP1 (DSHB, ID4Bc), anti-RNase H2A (Origene, TA306706), anti-H-Ras (Santa Cruz, sc-29), and anti-PARP1 (Cell Signaling, #9542). To ensure equal loading amounts, membranes were stripped and re-probed with anti β-actin (Cell Signaling Technology, #4967). Antibody dilutions are provided in Supplementary Table B.

**Neurological and Behavioral Analyses**

The neurological as well as behavioral tests were performed at the German Mouse Clinic (22, 23). The test pipeline started with 39 mice (12 male mutants, 7 male controls, 10 female mutants, and 10 female controls). Mice were maintained in IVC cages with water and standard mouse chow (Altromin no. 1314) according to the GMC housing conditions and German laws (for details, check https://www.mouseclinic.de/about-gmc/mouse-husbandry/index.html). All tests performed at the GMC were approved by the responsible authority of the Regierung von Oberbayern (animal license no. 46-16). Welfare-related monitoring of experimental animals was performed according to the animal license. Sample size of the experiments was calculated and documented in the approval 46-16.

**Open Field**

The Open Field analysis was carried out as described previously (24, 25). It consisted of a transparent and infra-red light permeable acrylic test arena with a smooth floor (internal measurements: 45.5 cm × 45.5 cm × 39.5 cm). Illumination levels were set at approx. 150 lux in the corners and 200 lux in the middle of the test arena. Data were recorded and analyzed using the ActiMot system (TSE, Bad Homburg, Germany).

**Prepulse Inhibition (PPI) of the Acoustic Startle Response**

Animals were separated based on sex, but not genotype. PPI was assessed automatically using an automated startle apparatus setup (Med Associates Inc., VT, USA) including four identical sound-attenuating cubicles. The protocols were written using the Med Associates “Advanced Startle” software. Experiments were carried out between 08:30 h and 17:00 h. Background noise was
65 dB, and startle pulses were bursts of white noise (40 ms). A session was initiated with a 5-min-acclimation period followed by five presentations of leader startle pulses (110 dB) that were excluded from statistical analysis. Trial types for the PPI included four different prepulse intensities (67, 69, 73, 81 dB); each prepulse preceded the startle pulse (110 dB) by a 50 ms inter-stimulus interval. Each trial type was presented 10 times in random order, organized in 10 blocks, each trial type occurring once per block. Inter-trial intervals varied from 20 to 30 s. This protocol is based on the protocol used in IMPRESS from the International Mouse Phenotyping Consortium (IMPC, see www.mousephenotype.org/impress), adapted to the specifications of our startle equipment.

**Beam Ladder**

The beam ladder consists of two Plexiglas screens connected with several metal beams of variable distance. The test is used to evaluate skilled walking of the mice. Mice traverse the ladder and foot slips of fore paws and hind paws are counted separately as well as traversing time.

Modified SHIRPA analysis, rotarod, auditory brain stem response (ABR), grip strength, and hot plate testing was performed as described (26).

**Experimental Autoimmune Encephalomyelitis (EAE)**

Mice were immunized subcutaneously at the tail basis with 50 µg MOG35–55 peptide (Gene Script) emulsified in Complete Freund's adjuvant (Difco) supplemented with 1.1 mg of heat-inactivated *Mycobacterium tuberculosis* (Difco). At the day of immunization and again 2 days later, mice received an intraperitoneal injection of 200 ng pertussis toxin (List Biological Laboratories). Clinical signs of disease were assessed daily and graded on a scale from 0 to 6 as follows: 0, no disease; 0.5, partial loss of tail tonicity; 1, complete loss of tail tonicity; 1.5, partially impaired righting reflex on attempt to roll over (within 3 s); 2, impaired righting reflex; 2.5 partial hind limb paresis resulted in staggering gait; 3, complete hind limb paresis; 3.5, complete hind limb paralysis; 4, unilateral forelimb paresis; 4.5, complete forelimb paresis; 5, moribund, and 6, dead animal. Experiments were performed in accordance with the guidelines of the central animal facility institution (TARC, University of Mainz) and approved by the local authorities under the license number G 13-1-098.

**Statistics**

All data are shown as mean ± SEM. Statistical analysis was performed with GraphPad Prism 5 using two-tailed Student’s t-test unless indicated otherwise in the figure legends. For all tests, p-values less than 0.05 were considered statistically significant. The phenotyping screen at the GMC was mainly designed as a high throughput screen for new phenotypic alterations, a correction for multiple testing of the various parameters was not performed. If not stated otherwise, data were analyzed using R software (Version 3.0.2; Foundation of Statistical Computing, Vienna, Austria).

**RESULTS**

**Generation of Conditional Knockout Mice Lacking RNase H2 in the Brain**

As information regarding RNase H2 expression in the mammalian brain is scarce, we first tracked RNase H2 protein expression in the mouse brain using a rabbit antiseraum raised against the RNase H2 holoenzyme. RNase H2 was expressed throughout the entire murine brain with highest expression in the hindbrain, the cerebellum, the hippocampus, and the cerebral cortex (Figure 1A). Notably, particularly high expression was observed in the subgranular zone (SGZ) of the hippocampal dentate gyrus (dg), a region typically associated with adult hippocampal neurogenesis and proliferation. To further narrow down RNase
H2 expression, we applied double-immunofluorescence staining of RNase H2 with NeuN, a neuronal marker, and the astrocytic marker GFAP (Figure 1B). RNase H2 extensively co-localized with NeuN in both the cerebral cortex and the dg (Figure 1B). Remarkably, those cells with the highest expression in the SGZ were negative for GFAP and NeuN, a marker for more mature neurons, indicating that these cells were immature neuronal precursor cells (Figure 1B). Accordingly, these abundantly RNase H2 expressing cells were positive for Ki67, a marker for dividing cells (Figure 1C). Immunohistochemistry of diseased brain sections revealed that astrocytes secrete the pathogenic interferon α in AGS patients (6), and transgenic mice overexpressing interferon α from the supposedly astrocyte-specific GFAP-promoter exhibit clinical signs reminiscent of AGS (7). To establish a mouse model of AGS, we conditionally deleted RNase H2 in the mouse brain by intercrossing RNase H2B-flox mice with GFAP-Cre transgenic mice (Figure 2A). The resulting animals carrying homozygous RNase H2B deletions were designated RNase H2ΔGFAP mice. RNase H2ΔGFAP mice were viable, fertile, and exhibited no obvious phenotype. Offspring was generated in the expected Mendelian ratio (Figure 2B). Western Blot and immunofluorescence analysis revealed robust expression of RNase H2 in wild-type astrocytes, while astrocytes isolated from RNase H2ΔGFAP mice completely lacked the nuclease (Figures 2C,D). Importantly, genetic ablation of RNase H2B has shown to be sufficient to disrupt expression of the entire holoenzyme (12). Absence of RNase H2 was confirmed in vivo by examining different brain regions using immunohistochemistry. RNase H2 was absent from the majority of cortical and hippocampal neurons as well as astrocytes in RNase H2ΔGFAP mice (Figure 2F). In keeping with this, western blot analysis of whole brain lysates revealed a marked downregulation of RNase H2 protein expression (Figure 2E). Although leakiness of the

**FIGURE 1** | Expression of RNase H2 in the murine central nervous system. (A) Sagittal sections from p21 mouse brains were stained with an RNase H2-specific antiserum followed by a biotinylated secondary antibody, streptavidin-coupled HRP, and developed with the chromogenic substrate 3,3′-Diaminobenzidine (DAB). Note the high expression of RNase H2 in the corpus callosum (cc) and hippocampus, with particularly high expression in the subgranular cell layer (sgcl) of the dentate gyrus (dg). Cornu Ammoni (CA), molecular layer (ml), granular layer (gl).

(B) Co-immunofluorescence staining for RNase H2 (red) with the neuronal marker NeuN (green, left panel) and astroglia marker GFAP (green, right panel) shows striking co-localization of RNaseH2 in neuronal cells expressing NeuN in both the cerebral cortex and dg. Scale bar = 150 µm (upper four panels), 10 µm (lower two panels)

(C) Co-immunofluorescence staining for RNase H2 shows highest expression of RNase H2 in Ki67-positive proliferating cells. Scale bar = 30 µm.
technically astrocyte-specific GFAP-Cre line has been reported previously (27), we were surprised by the efficient ablation of RNase H2 in neuronal cells of RNase H2ΔGFAP mice. To validate the prominent neuronal expression of RNase H2, we generated a second conditional RNase H2 knockout mouse line by crossing RNase H2ΔGFAP mice to Emx1-Cre transgenic mice, in which Cre
recombinase is active predominantly in neurons of the neocortex and hippocampus. Ablation of neuronal RNase H2 was effective in RNase H2ΔEml mice and largely mirrored the deletion pattern seen in RNase H2ΔGFAP mice (Figure S1A in Supplementary Material). However, because of the strong clinical link between astrocytes and AGS pathology, we focused in the present work on RNase H2ΔGFAP animals.

RNase H2ΔGFAP Mice Display No AGS-Like Phenotype

Aicardi–Goutières syndrome is characterized by fundamental morphological changes of the brain, including microcephaly, cerebral calcifications, and white matter abnormalities such as atrophy (1). However, baseline H&E histology revealed no apparent differences between RNase H2ΔGFAP and control brains (Figure S2A in Supplementary Material). Chronic neuroinflammation associated with activation of the type I interferon axis is a defining hallmark of AGS (2). Brains of 3 months old RNase H2ΔGFAP mice did not show signs of astrogliosis or microgliosis compared to control littermates, as assessed by GFAP and Iba-1 immunostaining, respectively (Figures 3A,B). Importantly, qPCR analysis revealed similar expression of selected ISGs in RNase H2ΔGFAP and control brains (Figure 3C). We additionally performed detailed neurological and behavioral tests with RNase

**FIGURE 3** Absence of neuroinflammation in RNase H2ΔGFAP mice. (A) Immunohistochemistry for the astrocyte marker GFAP reveals absence of significant astrogliosis in the hippocampus, cerebral cortex, cerebellum, and thalamus of RNase H2ΔGFAP mice. Astrogliosis would present as increased expression of GFAP, cellular hypertrophy with changes of astrocyte morphology or proliferation of astrocytes. (B) Comparable Iba-1 staining between RNase H2ΔGFAP and control brains indicates absence of microgliosis in RNase H2ΔGFAP mice (age 3 months). Inserts represent magnifications of individual hippocampal microglia showing similar morphology in both genotypes. Scale bar = 150 µm. (C) Comparable mRNA expression of IFIT1, IRF7, and CXCL10 in RNase H2ΔGFAP and control brains (N = 1), as quantified by qPCR. ISG expression was normalized to GAPDH. Whole brain RNA was prepared from P3-4 pups. Error bars are SEM, t-test (N = 5 brains/genotype).
H2ΔGFAP animals (summarized in Figure S2B in Supplementary Material). However, behavioral and neurological examination of RNase H2ΔGFAP mice only sporadically revealed subtle sex-specific effects of unclear relevance, which did not resemble the severe disabilities observed in AGS (summarized in Figure S2B, detailed in Figures S3A–F and Neurology Data in Supplementary Material). Disease progression in AGS patients with the same mutation often differs significantly, even within families (2). It has, therefore been suggested that external factors, such as viral infections or other environmental cues, may influence the course of disease or even trigger disease onset. To test this, we subjected mice to EAE, a mouse model of multiple sclerosis. However, following immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55), we observed no major differences in disease progression or clinical parameters between RNase H2ΔGFAP and control mice (Figures S4A–C in Supplementary Material). In conclusion, RNase H2ΔGFAP mice did not display AGS-related pathology and failed to show exacerbated disease upon induction of CNS autoimmunity. Furthermore, RNase H2ΔEmx1 mice developed normally and had no obvious phenotype. Similar to RNase H2ΔGFAP mice, RNase H2ΔEmx1 animals lacked active astrogliosis or interferon signature (Figures S1A,B in Supplementary Material), resulting in a second brain-specific RNase H2 knockout mouse line that fails to recapitulate major signs of the human disease.

**Astrocytes Derived From RNase H2ΔGFAP Mice Show Cellular Defects Consistent With Aicardi–Goutières Syndrome-Like Autoinflammation**

Skin fibroblasts from AGS patients bearing RNase H2 mutations displayed signs of DNA damage, culminating in the development of premature senescence in diseased fibroblasts (28). Given the established link between DNA damage and type I interferon expression, it has been hypothesized that in fact DNA damage might represent the prime trigger of the pathogenic type I interferon production in AGS (12, 28, 29). We sought to investigate whether RNase H2ΔGFAP astrocytes would recapitulate some of the features of AGS patient cells. We, therefore isolated astrocytes from neonatal RNase H2ΔGFAP and control brains, with primary cell cultures consistently containing >90% GFAP-positive murine astrocytes (a representative astrocyte preparation is shown in Figure S4D in Supplementary Material). As shown above, cultured astrocytes from RNase H2ΔGFAP mice were devoid of RNase H2 (Figures 2C,D). In contrast to RNase H2ΔGFAP brains, which failed to show significant ISG upregulation (Figure 3C), we observed a robust interferon signature in cultured RNase H2ΔGFAP astrocytes (Figure 4A). Importantly, assessment of cerebral ISG expression was carried out at the same developmental stage as RNase H2ΔGFAP astrocyte isolation (P3/4 pups). Using flow cytometry and immunofluorescence, we monitored phosphorylation of histone H2AX, a common marker for DNA double-strand breaks, and detected extensive DNA damage in RNase H2ΔGFAP astrocytes (Figures 4B,C). In line with increased DNA damage, RNase H2ΔGFAP astrocytes showed a marked reduction in their proliferative capacity, as assessed by EdU incorporation (Figure 4D). Western blot analysis revealed that RNase H2ΔGFAP astrocytes did not exhibit caspase-mediated PARP-1 cleavage, indicating that RNase H2-deficient astrocytes did not undergo apoptosis (Figure 4E). In contrast, RNase H2ΔGFAP astrocytes developed an enlarged and flattened morphology, which is consistent with cellular senescence (Figure 5A). In keeping with this, transcript levels of several senescence-associated genes were upregulated in RNase H2ΔGFAP astrocytes (Figure 5B). A hallmark of senescent cells is the enlargement of their lysosomal compartment, which is typically assessed by measuring activity of acidic β-galactosidase (30). However, high background levels of acidic β-galactosidase already in control astrocytes precluded a detailed analysis of this marker (data not shown). Instead, we observed increased mRNA and protein levels of the lysosomal proteins LAMP1 and Cathepsin A in RNase H2ΔGFAP astrocytes, which likewise suggested elevated lysosome biogenesis in the absence of RNase H2 (Figures 5C,D). Importantly, control astrocytes that had been driven into oncogene-induced senescence (OIS) by retroviral transduction with oncogenic H-Ras showed comparable upregulation of senescence-associated genes (Figures 5E–G).

It has been hypothesized that AGS might require an environmental trigger for manifestation (see above). To test this hypothesis at the cellular level, we challenged isolated astrocytes “primed by DNA damage” with bacterial (LPS) and viral (poly I:C) antigens. DNA damage was inflicted either by treatment with the chemotherapeutic drug doxorubicin or RNase H2 loss (in RNase H2ΔGFAP astrocytes). Importantly, when isolated astrocytes were primed by DNA damage prior to LPS or poly I:C treatment, enhanced activation of the type I interferon axis was observed (Figures 5H,I). Taken together, cultured murine astrocytes lacking RNase H2 exhibited increased ISG expression, extensive DNA damage, and signs of cellular senescence, all of which has previously been reported for mutant RNase H2 patient cells (28). Moreover, RNase H2-deficient astrocytes adapted a primed state that further amplified the innate immune response elicited by bacterial or viral antigens.

**DISCUSSION**

Aicardi–Goutières syndrome is a severe autoimmune childhood disorder resulting in profound physical and intellectual disabilities. AGS is of genetic origin and mainly affects the brain, although extraneurolological symptoms such as chilblain lesions of the skin are frequent (2). The disease trigger is most likely a chronic overactivation of the type I interferon system, which is supported by the AGS-like phenotype of transgenic mice overexpressing interferon α in the CNS (7). All genes associated with AGS are involved either in nucleic acid metabolism or detection, with mutations in the endoribonuclease RNase H2 accounting for >50% of cases (2). In addition, gene variants in the AGS genes TREX1 and RNASEH2 have also been associated with SLE, underlining the considerable phenotypic overlap between the two disease entities (28, 31). RNase H2 has two distinct enzymatic activities. While it can cleave the RNA moiety of an RNA/DNA hybrid (containing >4 consecutive ribonucleotides), it is
also capable of initiating the excision of single ribonucleotides embedded in a DNA duplex (32). The latter enzyme activity appears to be the main physiological function of RNase H2, as mouse embryos deficient for RNase H2 strongly accumulate genome-embedded ribonucleotides leading to widespread DNA damage (12). In this context, replicative DNA polymerases have been shown to be much more promiscuous as previously anticipated, resulting in the establishment of misincorporated ribonucleotides as the most frequent naturally occurring DNA lesions (12, 33). In line with this, RNase H2 expression is particularly strong in tissues with a high proliferative turnover, such as gut, skin, testis, and developing brain (12). Given this strong link between RNase H2 expression and proliferation, we were surprised by the high abundance of RNase H2 in postmitotic neurons. A possible explanation for the unexpectedly strong expression in postmitotic neurons could be a function of RNase H2 independent of DNA replication such as R-loop resolution during transcription (34) or RNA/DNA hybrid degradation during double strand break repair (35). However, this potential alternative function of RNase H2 in the brain is apparently not crucial for neuronal homeostasis, as neuronal RNase H2 ablation did not result in an obvious phenotype (this study). RNase H2 knockout mice die in utero as a consequence of a p53-mediated growth arrest starting around gastrulation (11, 12). As due to their early embryonic lethality RNase H2 null mice preclude detailed analysis of AGS pathology, we generated conditional knockout mice lacking RNase H2 in the brain, the most affected organ in AGS. To that end, we intercrossed floxed RNase H2B mice to animals expressing Cre under the human GFAP promoter, thereby targeting essentially the same cell types as in the seminal study on brain-specific interferon α overexpression (7). In RNase H2ΔGFAP mice, RNase H2 ablation was not only achieved in astrocytes

**FIGURE 4** RNase H2ΔGFAP astrocytes recapitulate features of Aicardi–Goutières syndrome patient cells. (A) Increased expression of selected interferon-stimulated genes (ISGs) in primary RNase H2ΔGFAP astrocytes 7 days post isolation, as quantified by qPCR. ISG transcript levels in RNase H2ΔGFAP astrocytes were normalized to GAPDH and indicated relative to control astrocytes (x = 1). Error bars represent SEM, *p < 0.05, t-test (n = 3). (B) Representative Immunofluorescence analysis (n = 3) showing extensive DNA damage in RNase H2ΔGFAP astrocytes 7 days post isolation, as evidenced by histone H2AX phosphorylation (γH2AX). Wild-type astrocytes treated with 1 µM Doxorubicin for 24 h served as positive control. DAPI as nuclear counterstain. (C) Representative flow cytometry histogram showing increased DNA damage in RNase H2ΔGFAP astrocytes, compared to control astrocytes (n = 3). Unstained cells were used as negative control. (D) EdU incorporation assay (4 h pulse) revealed significantly fewer RNase H2ΔGFAP astrocytes in S-Phase 7 days post isolation. Error bars represent SEM, **p < 0.01, t-test (n = 4). (E) Immunoblot showing the absence of apoptosis in RNase H2ΔGFAP astrocytes, as evidenced by lack of PARP-1 cleavage (n = 2). PARP-1 is a caspase-3 substrate. Control astrocytes treated with 25 µM Doxorubicin for 24 h served as positive control, while β-Actin levels indicated equal loading. fl = full length, cl = cleaved.
**Figure 5** Continued
but also in almost all cortical and hippocampal neurons. The efficient deletion of RNase H2 in neurons of RNase H2ΔGFAP mice somewhat surprised us, although recombination activity outside astrocytes has previously been reported for this Cre line (27). Consequently, the RNase H2 deletion pattern observed in RNase H2ΔGFAP mice strongly resembled a second, neuron-specific RNase H2 mutant mouse line we generated in this study (RNase H2ΔEmx1). Despite a widespread absence of RNase H2 in astrocytes and neurons, RNase H2ΔGFAP mice did not develop clinical signs resembling AGS, such as neuroinflammation, brain calcifications, or leukodystrophy. The lack of an overt phenotype in RNase H2ΔGFAP mice is remarkable, given (1) the essential role of RNase H2 in prenatal development and (2) the severe consequences of only hypomorphic RNase H2 mutations in AGS patients. This discrepancy between mouse model and human disease does not only hold true for RNase H2, but also for other AGS-associated genes. In a nutshell, all AGS mouse models described so far fail to recapitulate the strong CNS involvement of the human disease. The reason for this striking difference in disease course between the two species is not known at present and can only be speculated on. At least for RNase H2, however, our study might offer a possible explanation for this apparent conundrum. Whereas RNase H2ΔGFAP mice did not exhibit AGS-related disease signs in vivo, RNase H2ΔGFAP astrocytes isolated from the same animals showed cellular defects akin to AGS patient cells, including DNA damage, premature senescence, and increased ISG expression. In this context, it is important to note that RNase H2ΔGFAP astrocytes were cultured under mitogenic conditions, which is in stark contrast to the largely postmitotic nature of resident neurons and astrocytes in RNase H2ΔGFAP brains. It is therefore plausible that active proliferation is a prerequisite for the development of cellular features reminiscent of AGS. In support of this, recent reports have shed light on the role of microRNA in activating the innate immune system upon DNA damage, which in two studies also included DNA damage caused by RNase H2 loss (36–38). Importantly, generation of these immunogenic microRNAs was strongly dependent on cellular proliferation (36–38). This reliance on proliferation could explain why humans with only hypomorphic RNase H2 mutations develop AGS, whereas mice carrying the same patient mutations (16, 17) or even completely lack RNase H2 in large parts of the brain (this study) do not show AGS-like features: Due to the larger size of the human brain neurogenesis is faster and involves more cell divisions than in the murine brain (39). It is, therefore conceivable that the degree of neuronal proliferation is just not sufficient for the establishment of disease symptoms in the much smaller murine brain. However, further experiments are clearly needed to test this hypothesis. In aggregate, primary RNase H2ΔGFAP astrocytes can serve as a valid cellular model of AGS, since they (1) display similar defects as RNase H2 mutant AGS patient cells and (2) constitute the very cell type responsible for pathogenic interferon α production in AGS individuals. In addition, DNA damage renders RNase H2-deficient astrocytes more sensitive toward foreign antigens, which could help explain the phenotypic variability among AGS patients bearing the same mutation and also why AGS sometimes seems to require an exogenous trigger in order to manifest.

**ETHICS STATEMENT**

All statements regarding the mouse work have been included in the Section “Materials and Methods” of the manuscript.

**AUTHOR CONTRIBUTIONS**

KB, MD, and BR designed the study. KB, MD, TR, LB, LG, SH, KK, CB, and MG performed experiments and analyzed the data. AW, HF, VG-D, MHA, and BR planned the projects and supervised the experiments. KB, MD, and BR wrote the manuscript.

**ACKNOWLEDGMENTS**

We thank Annett Lickert and Stefanie Schnell for excellent technical assistance.

**FUNDING**

This work was supported by grants from the Deutsche Forschungsgemeinschaft, Bonn, Germany (Project grant RA 2404/1-1) and the Cluster of Excellence “Inflammation at Interfaces”. The German Mouse Clinic (GMC) is funded by the German Federal Ministry of Education and Research (Infrafrontier grant 01KX1012).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00587/full#supplementary-material.
REFERENCES

1. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet (2009) 85(5):771–9. doi:10.1016/j.ajhg.2009.05.008

2. Crow YJ, Chase DS, Loevenstein Schmid I, Szyfkevich M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A (2015) 167A(2):296–312. doi:10.1002/ajmg.a.36887

3. Crow YJ, Chase DS, Loevenstein Schmid I, Szyfkevich M, Forte GM, Gornall HL, et al. Characterization of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 12(12):1159–69. doi:10.1016/s1474-4422(13)70258-8

4. Rice GJ, Forte GM, Szyfkevich M, Chase DS, Aebly A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome. Annu Rev Immunol (2017) 35:313–36. doi:10.1146/annurev-immunol-051116-052331

5. Rice GI, Forte GM, Szyfkevich M, Chase DS, Aebly A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 12(12):1159–69. doi:10.1016/s1474-4422(13)70258-8

6. von Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

7. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

8. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

9. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

10. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

11. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

12. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

13. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

14. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

15. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

16. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

17. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

18. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

19. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.

20. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 161(9):5016–26.